Literature DB >> 31653165

Relationship between Socioeconomic Status and Prevalent Prostate Cancer in the South Korea.

Hee-Won Hur1, So-Yeon Ryu2, Jong Park2, Seong-Woo Choi2.   

Abstract

BACKGROUND: Prostate cancer prevalence recently has increased among male adults in South Korea. But, few study has evaluated the reason. Therefore, we investigated the relationship between socioeconomic status and prevalent prostate cancer.
METHODS: This study enrolled 16,215 males aged 40 years and over who took part in the Korean National Health and Nutrition Examination Survey 2007-2016. In addition, we obtained the 2000-2016 age-standardized incidence rate and age-standardized mortality rate of prostate cancer from the Korean Statistical Information Service.
RESULTS: After adjusting for other covariates, prevalent prostate cancer was significantly associated with monthly household income (OR 3.71, 95% confidence interval [CI] 1.48-9.30, for highest vs. lowest) and significantly associated with education level (OR 3.66, 95% CI 1.54-8.70, for ≥ 13 vs. ≤ 6). In the analysis of the age-standardized incidence rate and the age-standardized mortality rate, the age-standardized incidence rate has soared from 2000 to 2011 and then decreased gradually, but the age-standardized mortality rate did not change.
CONCLUSION: In our results, prevalent prostate cancer increased significantly with socioeconomic status and the increase in prevalent prostate cancer may be attributable to earlier detection rather than to a real increase in prevalence.

Entities:  

Keywords:  Educational status; Prostatic Neoplasms; income; social class

Mesh:

Year:  2019        PMID: 31653165      PMCID: PMC6982686          DOI: 10.31557/APJCP.2019.20.10.3137

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


Introduction

Globally, prostate cancer is the most common male cancer (Global Cancer Observatory, 2018) and the number of male patients diagnosed with prostate cancer during the year 2012 was about 1.1 million, and about 70% of prostate cancer cases occurred in developed countries (Global Cancer Observatory, 2018). In the United States, the incidence of prostate cancer peaked in 1992 and subsequently declined, but the prostate cancer incidence is still the highest in American men (Cronin et al., 2018). The new case of prostate cancer in Korea was 3,487 in 2005 (Jung et al., 2009) and increased about 3.4 times to 11,800 in 2016 (Jung et al., 2019). Age has been known to be the most essential risk factor for prostate cancer; the incidence increases with age after 50 years (Kim, 2004). Also, the incidence of prostate cancer is higher in blacks than in whites, with early onset and malignancy, leading to higher mortality rates (Schwartz et al., 2003). However, none of the risk factors for prostate cancer are clearly known except for age, race, and family history (Platz and Giovannucci, 2006). A westernized lifestyle, obesity, lack of exercise and activity have been reported as risk factors, but the results have been inconsistent (Perez-Cornago et al., 2017; Malik et al., 2018). Socioeconomic status (SES) is related to health. The lower the SES is, the lower the self-reported health (Borg and Kristensen, 2000) and the increased incidence of illness and mortality (Saydah et al., 2013). However, the relationship between socioeconomic level and cancer incidence and mortality is unclear, and prostate cancer studies have shown varying results. In some studies, the incidence of prostate cancer increased with SES (Cheng et al., 2009), while in other studies it decreased with a higher SES (Baquet et al., 1991), and still other studies found no association between SES and prostate cancer (Williams and Horm, 1977; Mackillop et al., 2000). However, most of these studies have been performed in Western populations and few studies have been conducted in Korea, where prostate cancer has soared recently. Specifically, few study has evaluated whether prostate cancer in Korea has actually increased because of a specific cause or as a product of early detection. For thyroid cancer, which showed a similar surge, many experts warned that overdiagnosis should be suspected (Choi et al., 2013; Ahn et al., 2014). Therefore, this study assessed the association of prevalent prostate cancer with SES using the following two data sets: 1) the 2007–2016 Korea National Health and Nutrition Examination Survey (KNHANES), 2) the prostate cancer age-standardized incidence rate (AIR) using cancer registration statistics, and the prostate cancer age-standardized mortality rate (AMR) using cause-of-death statistics released by the Korean Statistical Information Service (KOSIS).

Materials and Methods

Subjects This study used the 2007–2016 KNHANES data on SES, the prevalent case of prostate cancer, and health behaviors and 2000-2016 KOSIS data on the AIR and AMR of prostate cancer. The details of KNHANES are already demonstrated in previous publication (Kweon et al., 2014). The Korea Centers for Disease Control and Prevention (KCDCP) annually conducts the KNHANES using a sampling design to produce health statistics representative of residents of the Republic of Korea. The KNHANES consisted with the health and nutrition interview and health examination. The health and nutrition interview are conducted by trained interviewers using questionnaires, and the health examinations are performed by trained medical staff. The 2007–2016 surveys included 83,503 participants. After excluded 44,501 women, 19,216 people under 40, and 3,571 people without income, education, or prostate cancer screening data, we analyzed 16,215 men aged 40 years or older. Measurements Trained investigators interviewed the subjects individually using a questionnaire. A person who answered ‘yes’ to a question about being diagnosed with prostate cancer was defined as a patient with prostate cancer. Monthly household income was classified into quartiles. Education level was divided into ≤ 6, 7–9, 10–12, and ≥ 13 years. BMI was presented by dividing the weight in kilograms by the square of the height in meters. Marriage status was classified as unmarried and married; residence area was divided into urban and rural areas. Current smoking was defined as people who smoked or smoked occasionally, and monthly drinking was defined as having one or more drinking experiences during the previous month. Physical activity was defined as walking for more than thirty minutes at one time and more than 5 times per week. Health checkup in the previous 2 years was defined as a case in which a health checkup had been conducted in the past 2 years; cancer examination in the prior 2 years was defined similarly. Hypertension was defined as taking a hypertensive medicine or blood pressure above 140/90 mmHg; diabetes mellitus was defined as taking a diabetes medicine or using insulin, or fasting blood glucose above 126 mg/dL. Dyslipidemia was defined as taking a dyslipidemic medicine or one of the following four: total cholesterol above 240 mg/dL, triglycerides above 200 mg/dL, low-density lipoprotein cholesterol above 160 mg/dL, and high-density lipoprotein cholesterol below 40 mg/dL. Cardiovascular disease was defined as having been diagnosed with myocardial infarction or angina pectoris or stroke. Other cancer was defined as having been diagnosed with a cancer other than prostate cancer. The AIR and AMR of prostate cancer The AIR and AMR of prostate cancer in 2000–2016 were analyzed using cancer registration and cause-of-death statistics released on the KOSIS web page (Korean Statistical Information Service, 2018). Statistical analysis The survey responses were weighted based on a multilevel, multiple, probability sampling design to represent for nationally representative prevalence estimates of the Korean population. The estimates were calculated with consideration for the primary sampling unit, stratification variables, and sampling weights. Data were expressed as estimated percentages (standard errors [SEs]) or mean±standard deviation. The distributions of each variable according to the quartiles of monthly household income and education level were analyzed using the analysis of variance. The associations of prevalent prostate cancer with the quartiles of monthly household income and education level were analyzed using a multivariate logistic regression analysis. Model 1 was adjusted for age, BMI, survey year, marital status, and residence area. Model 2 was additionally adjusted for current smoking, monthly drinking, physical activity, health checkup in the prior 2 years, cancer examination in the prior 2 years, hypertension, diabetes, dyslipidemia, cardiocerebrovascular disease, and other cancer. Model 3 was additionally adjusted for education level or monthly household income. A P-value < 0.05 was considered statistically significant. Statistical analysis was performed using SPSS ver. 18.0. General Characteristics of the Subject Characteristics of Subjects by Quartiles of Monthly Household Income All values are given as estimated percentage(standard error); a, Physical activity was indicated as `yes' when the subject walked for more than 30 min at a time and more than five times per week; b, Hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or taking antihypertension medication; c, Diabetes was defined as fasting serum glucose ≥ 126 mg/dL or taking insulin or oral diabetes medication; d, Dyslipidemia was defined as taking a dyslipidemic medicine or total cholesterol ≥ 240 mg/dL or triglycerides ≥ 200 mg/dL or low-density lipoprotein cholesterol ≥ 160 mg/dL or high-density lipoprotein cholesterol ≤ 40 mg/dL Characteristics of Subjects by Education Level All values are given as estimated percentage(standard error); a, Physical activity was indicated as `yes' when the subject walked for more than 30 min at a time and more than five times per week; b, Hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or taking antihypertension medication; c, Diabetes was defined as fasting serum glucose ≥ 126 mg/dL or taking insulin or oral diabetes medication; d, Dyslipidemia was defined as taking a dyslipidemic medicine or total cholesterol ≥ 240 mg/dL or triglycerides ≥ 200 mg/dL or low-density lipoprotein cholesterol ≥ 160 mg/dL or high-density lipoprotein cholesterol ≤ 40 mg/dL. The ORs for Prevalent Prostate Cancer by Quartiles of Monthly Household Income and Education Level a, Adjusted by age, survey year, marital status and residential area; b, Adjusted by Model 1 variables plus BMI, current smoking, alcohol intake in past month, physical activity, health checkup in the prior 2 years, cancer examination in the prior 2 years, hypertension, diabetes, dyslipidemia, cardiocerebrovascular disease and other cancer; c, Adjusted by Model 2 variables plus education level or monthly household income level Age-Standardized Incidence and Mortality Rate of Prostate Cancer in 2000-2016 Ethics statement This study was conducted according to the Declaration of Helsinki and all subjects provided informed consent for their data use. The KCDCP ethics committee approved the study protocol (2007-02CON-04-P, 2008-04EXP-01-C, 2009-01CON-03-2C, 2010-02CON-21-C, 2011-02CON-06-C, 2012-01EXP-01-2C, 2013-07CON-03-4C, 2014-12EXP-03-5C, 2015-01-02-6C).

Results

General characteristics of the subjects Fifty-eight patients were diagnosed with prostate cancer. Their mean age was 55.0 ± 0.1 years, and their mean BMI was 24.2 ± 0.0 kg/m². The lowest to highest quartiles of monthly household income contained 17.3, 24.9, 27.4, and 30.4%, respectively. The education level was ≤ 6 for 19.9%, 7–9 years for 15.0%, 10–12 years for 34.1%, and ≥ 13 years for 31.0% (Table 1).
Table 1

General Characteristics of the Subject

VariablesNumbere%(SE) or Mean±SD
Total16,215
Prostate cancer patients690.3 (0.0)
Age (year)55.1±0.1
40-494,38937.6 (0.5)
50-646,29241.8 (0.5)
≥655,53420.6 (0.4)
BMI (kg/m2) 24.2±0.0
<18.54642.4 (0.1)
18.5-24.99,81658.7 (0.5)
25.0-29.95,48035.7 (0.4)
≥304473.2 (0.2)
Survey year
20077914.7 (0.5)
20081,7799.8 (0.6)
20092,11410.4 (0.7)
20101,80710.4 (0.8)
20111,79110.7 (0.8)
20121,63510.5 (0.7)
20131,53710.5 (0.7)
20141,44210.3 (0.7)
20151,56610.8 (0.7)
20161,75312.1 (0.4)
Monthly household income
Lowest 3,64117.3 (0.4)
Medium-lowest 4,12524.9 (0.5)
Medium-highest4,04427.4 (0.5)
Highest 4,40530.4 (0.6)
Education (year)
≤64,13119.9 (0.4)
7-92,57215.0 (0.4)
10-125,03334.1 (0.5)
≥134,47931.0 (0.6)
Marital status
Single1,88813.6 (0.4)
Married14,31686.4 (0.4)
Residential area
Urban11,95377.8 (1.0)
Rural4,26222.2 (1.0)
Current smoking 7,76849.4 (0.5)
Alcohol intake in past month12,56280.5 (0.4)
Physical activitya 6,79639.9 (0.5)
Health checkup in the prior 2 years11,21568.7 (0.5)
Cancer examination in the prior 2 years 9,37556.4 (0.5)
Hypertensionb 7,34741.9 (0.5)
Diabetesc 2,82116.1 (0.3)
Dyslipidemiad 2,69516.6 (0.3)
Cardiocerebrovascular disease 1,2575.9 (0.2)
Other cancer6633.3 (0.2)
Subject characteristics by quartiles of monthly household income Age, BMI, survey year, education level, marital status and smoking differed significantly according to the quartiles of monthly household income. In addition, urban dwellers, monthly household income, health checkup and cancer examination in the prior 2 years, and dyslipidemia significantly increased with increasing monthly household income, while current smoking, hypertension, diabetes, cardiocerebrovascular disease, and other cancer significantly decreased with increasing monthly household income (Table 2).
Table 2

Characteristics of Subjects by Quartiles of Monthly Household Income

VariablesMonthly household income
P-value
LowestMedium-lowestMedium-highestHighest
Prostate cancer patients0.4 (0.1)0.3 (0.1)0.1 (0.1)0.4 (0.1)0.072
Age (year)<0.001
40-4914.0 (0.8)35.6 (1.0)47.1 (1.0)45.7 (1.0)
50-6431.5 (1.0)43.4 (0.9)41.4 (1.0)47.2 (0.9)
≥6554.5 (1.0)21.0 (0.6)11.5 (0.5)7.1 (0.4)
BMI (kg/m2) <0.001
<18.54.9 (0.4)2.6 (0.3)1.9 (0.2)1.0 (0.2)
18.5-24.963.6 (0.9)59.9 (0.9)56.1 (0.9)57.0 (0.9)
25.0-29.928.6 (0.9)34.3 (0.9)38.3 (0.9)38.9 (0.9)
≥302.9 (0.4)3.3 (0.4)3.6 (0.4)3.0 (0.3)
Survey year<0.001
20076.6 (0.9)6.0 (0.7)4.3 (0.6)2.8 (0.5)
200814.1 (1.2)11.3 (0.9)9.9 (0.9)5.5 (0.7)
200913.3 (1.1)11.5 (0.8)10.3 (0.9)7.7 (0.8)
20109.1 (0.9)11.3 (1.0)11.6 (1.0)9.3 (0.9)
20119.5 (0.9)10.5 (0.9)11.0 (1.0)11.2 (1.0)
20129.3 (1.0)10.9 (1.1)11.2 (0.9)10.2 (1.0)
20139.7 (1.0)9.9 (0.8)11.4 (0.9)10.9 (1.0)
20149.1 (0.9)9.7 (0.9)10.6 (0.9)11.2 (1.1)
201510.1 (1.0)9.8 (0.9)9.1 (0.8)13.7 (1.2)
20169.4 (0.6)9.2 (0.6)10.7 (0.6)17.5 (1.1)
Education (year) <0.001
≤647.6 (1.0)23.7 (0.8)12.2 (0.6)6.0 (0.4)
7-920.3 (0.8)19.7 (0.8)14.2 (0.7)8.1 (0.5)
10-1222.4 (0.8)38.5 (0.9)39.1 (1.0)33.1 (1.0)
≥139.7 (0.6)18.0 (0.8)34.5 (0.9)52.9 (1.1)
Marital status<0.001
Single12.9 (0.7)11.1 (0.6)11.8 (0.7)17.8 (1.1)
Married87.1 (0.7)88.9 (0.6)88.2 (0.7)82.2 (1.1)
Residential area <0.001
Urban66.8 (1.6)74.6 (1.4)80.6 (1.2)85.1 (1.2)
Rural33.2 (1.6)25.4 (1.4)19.4 (1.2)14.9 (1.2)
Current smoking 53.0 (1.0)52.2 (1.0)50.6 (1.0)43.7 (1.0)<0.001
Alcohol intake in past month68.7 (0.8)79.6 (0.7)83.2 (0.7)86.3 (0.7)<0.001
Physical activitya 43.1 (1.0)40.4 (0.9)38.6 (0.9)38.7 (0.9)0.004
Health checkup in the prior 2 years56.6 (1.0)64.2 (0.9)70.5 (0.9)78.6 (0.7)<0.001
Cancer examination in the prior 2 years 46.6 (0.9)52.8 (0.9)56.0 (1.0)66.1 (0.9)<0.001
Hypertensionb 52.2 (1.0)42.5 (0.9)39.4 (1.0)37.2 (0.9)<0.001
Diabetesc 23.9 (0.9)16.9 (0.7)13.9 (0.7)12.7 (0.6)<0.001
Dyslipidemiad 14.9 (0.7)15.6 (0.7)15.8 (0.7)19.3 (0.8)<0.001
Cardiocerebrovascular disease 12.3 (0.6)5.3 (0.4)4.4 (0.4)3.8 (0.3)<0.001
Other cancer5.8 (0.4)3.4 (0.3)2.5 (0.3)2.2 (0.3)<0.001

All values are given as estimated percentage(standard error); a, Physical activity was indicated as `yes' when the subject walked for more than 30 min at a time and more than five times per week; b, Hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or taking antihypertension medication; c, Diabetes was defined as fasting serum glucose ≥ 126 mg/dL or taking insulin or oral diabetes medication; d, Dyslipidemia was defined as taking a dyslipidemic medicine or total cholesterol ≥ 240 mg/dL or triglycerides ≥ 200 mg/dL or low-density lipoprotein cholesterol ≥ 160 mg/dL or high-density lipoprotein cholesterol ≤ 40 mg/dL

Subject characteristics by education level Prevalent case of prostate cancer, age, BMI, survey year, monthly household income, current smoking, monthly drinking, cancer examination in the prior 2 years, and dyslipidemia differed significantly according to the education level. In addition, single person, urban dwellers and health checkup in the prior 2 years increased significantly with education level, while hypertension, diabetes, cardiocerebrovascular disease, and other cancer decreased significantly with increasing education level (Table 3).
Table 3

Characteristics of Subjects by Education Level

VariablesEducation (year)
P-value
≤67-910-12≥13
Prostate cancer patients0.5 (0.1)0.2 (0.1)0.2 (0.1)0.4 (0.1)0.015
Age (year)<0.001
40-497.5 (0.6)20.1 (1.1)44.8 (0.9)57.4 (0.9)
50-6443.9 (1.0)55.8 (1.2)41.8 (0.9)33.6 (0.9)
≥6548.6 (1.0)24.1 (0.9)13.4 (0.5)8.9 (0.4)
BMI (kg/m2) <0.001
<18.54.6 (0.4)2.4 (0.3)1.8 (0.2)1.6 (0.2)
18.5-24.964.1 (0.9)60.6 (1.2)58.1 (0.8)55.1 (0.9)
25.0-29.929.2 (0.9)34.2 (1.1)36.6 (0.8)39.5 (0.9)
≥302.1 (0.3)2.9 (0.4)3.6 (0.3)3.8 (0.3)
Survey year<0.001
20075.9 (0.8)5.4 (0.8)4.5 (0.6)3.9 (0.6)
200811.5 (1.0)11.2 (1.0)9.3 (0.7)8.5 (0.8)
200911.9 (1.0)11.4 (1.0)9.8 (0.8)9.5 (0.9)
201011.2 (1.2)11.5 (1.1)10.6 (0.9)9.1 (0.9)
201110.8 (1.1)11.8 (1.2)10.8 (0.9)9.8 (0.9)
201210.6 (1.1)10.0 (1.0)11.2 (0.9)9.8 (1.0)
20139.6 (0.9)10.3 (1.0)11.2 (0.9)10.5 (1.0)
20149.0 (0.9)9.9 (1.0)10.1 (0.9)11.4 (1.0)
201510.1 (1.0)8.3 (0.9)11.2 (0.9)12.0 (1.1)
20169.4 (0.6)10.3 (0.8)11.3 (0.6)15.5 (0.9)
Monthly household income <0.001
Lowest44.1 (1.0)25.0 (1.0)12.1 (0.5)5.8 (0.4)
Medium-lowest31.1 (0.9)34.3 (1.2)29.4 (0.8)15.2 (0.7)
Medium-highest16.1 (0.7)24.8 (1.1)30.1 (0.8)29.2 (0.8)
Highest8.7 (0.6)15.9 (1.0)28.4 (0.9)49.9 (1.0)
Marital status<0.001
Single9.8 (0.6)11.3 (0.8)13.7 (0.7)17.0 (1.0)
Married90.2 (0.6)88.7 (0.8)86.3 (0.7)83.0 (1.0)
Residential area<0.001
Urban64.9 (1.6)72.2 (1.5)78.4 (1.2)88.2 (0.9)
Rural35.1 (1.6)27.8 (1.5)21.6 (1.2)11.8 (0.9)
Current smoking 49.5 (1.0)50.3 (1.2)52.8 (0.9)45.2 (0.9)<0.001
Alcohol intake in past month71.0 (0.8)80.3 (0.9)84.0 (0.6)82.8 (0.7)<0.001
Physical activitya 40.9 (1.0)37.7 (1.2)39.6 (0.8)40.6 (0.9)0.152
Health checkup in the prior 2 years62.2 (1.0)64.0 (1.2)67.9 (0.8)76.0 (0.8)<0.001
Cancer examination in the prior 2 years 51.5 (1.0)55.4 (1.2)54.5 (0.8)62.0 (0.9)<0.001
Hypertensionb 50.7 (1.0)44.3 (1.1)41.6 (0.8)35.5 (0.8)<0.001
Diabetesc 21.4 (0.8)19.8 (0.9)15.2 (0.6)12.1 (0.6)<0.001
Dyslipidemiad 13.9 (0.7)17.9 (0.9)16.4 (0.6)18.0 (0.7)<0.001
Cardiocerebrovascular disease 10.2 (0.6)8.7 (0.6)4.8 (0.3)3.1 (0.3)<0.001
Other cancer5.5 (0.4)3.5 (0.4)2.7 (0.3)2.3 (0.2)<0.001

All values are given as estimated percentage(standard error); a, Physical activity was indicated as `yes' when the subject walked for more than 30 min at a time and more than five times per week; b, Hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or taking antihypertension medication; c, Diabetes was defined as fasting serum glucose ≥ 126 mg/dL or taking insulin or oral diabetes medication; d, Dyslipidemia was defined as taking a dyslipidemic medicine or total cholesterol ≥ 240 mg/dL or triglycerides ≥ 200 mg/dL or low-density lipoprotein cholesterol ≥ 160 mg/dL or high-density lipoprotein cholesterol ≤ 40 mg/dL.

Odds ratios (ORs) for prevalent prostate cancer by quartiles of monthly household income and education level After adjusting for age, BMI, survey year, marital status, residence area, current smoking, monthly drinking, physical activity, health checkup and cancer examination in the prior 2 years, hypertension, diabetes, dyslipidemia, cardiocerebrovascular disease, other cancer, and education level (Model 3), prevalent prostate cancer was significantly associated with monthly household income (OR 3.71, 95% confidence interval [CI] 1.48–9.30, for highest vs. lowest). When adjusted for the same variables and monthly household income (Model 3), prevalent prostate cancer was significantly associated with education level (OR 3.66, 95% CI 1.54–8.70, for ≥ 13 vs. ≤ 6) (Table 4).
Table 4

The ORs for Prevalent Prostate Cancer by Quartiles of Monthly Household Income and Education Level

VariablesModel 1a
Model 2b
Model 3c
OR (95%CI)OR (95%CI)OR (95%CI)
Monthly household income
Lowest111
Medium-lowest1.88 (0.90-3.91)1.95 (0.93-4.09)1.87 (0.90-3.87)
Medium-highest1.47 (0.61-3.53)1.53 (0.62-3.79)1.23 (0.48-3.15)
Highest5.54 (2.63-11.68)5.32 (2.44-11.61)3.71 (1.48-9.30)
Education (year)
≤6111
7-90.58 (0.17-1.91)0.67 (0.19-2.35)0.67 (0.19-2.35)
10-121.00 (0.40-2.53)1.08 (0.42-2.79)1.07 (0.41-2.78)
≥133.44 (1.47-8.03)3.73 (1.58-8.81)3.66 (1.54-8.70)

a, Adjusted by age, survey year, marital status and residential area; b, Adjusted by Model 1 variables plus BMI, current smoking, alcohol intake in past month, physical activity, health checkup in the prior 2 years, cancer examination in the prior 2 years, hypertension, diabetes, dyslipidemia, cardiocerebrovascular disease and other cancer; c, Adjusted by Model 2 variables plus education level or monthly household income level

The AIR and AMR of prostate cancer Figure 1 shows the AIR and AMR of prostate cancer from 2000 to 2016 in South Korea. AIR per 100,000 people increased from 7.3 in 2000 to 28.0 in 2011. It gradually decreased after 2011, reaching 25.5 in 2015 and increased again to 28.2 in 2016. However, the AMR per 100,000 did not change significantly from 4.2 in 2000 to 5.2 in 2016.
Figure 1

Age-Standardized Incidence and Mortality Rate of Prostate Cancer in 2000-2016

Discussion

This study investigated the relationship between SES and prevalent prostate cancer using 2007–2016 KNHANES data and the trends of the AIR and AMR in prostate cancer from 2000 to 2016 using cancer registration and cause-of-death data. In our results, prevalent prostate cancer increased significantly with household income and education level. Also, the AIR of prostate cancer increased sharply from 2000 to 2011, while there was little change in the AMR between 2000 and 2016. In the present study, prevalent prostate cancer increased with SES, as evaluated using monthly household income and education level. In previous studies, the relationship between SES and prostate cancer was inconsistent. An analysis in 65,506 patients diagnosed with any cancer using Korean National Health Insurance cancer registration data showed that the high-income group had a 1.28-fold higher risk of prostate cancer than the low-income group (Kim et al., 2012), which is similar to our results. However, in a study of the relationship between income and prostate cancer among adults living in the US and Canada, the authors presented that prostate cancer increased with income in the United States, while income and prostate cancer were not related in Canada (Mackillop et al., 2000). The reason for this difference is that genetic and cultural factors and the medical systems, especially universal health coverage, differ from country to country (Liu et al., 2001). In addition, the association between SES and prostate cancer seems to be influenced by the introduction of the PSA screening test. In the United States, the incidence of prostate cancer was not associated with SES before the introduction of the PSA test. However, since then, the higher the SES, the higher the incidence of prostate cancer (Liu et al., 2001). Even in study conducted in Finland, where economic inequality is low and public health care is universal, the researchers demonstrated that more educated people underwent more PSA tests and had a higher incidence and lower mortality rate of prostate cancer than less educated people (Kilpeläinen et al., 2016). Our finding that the prevalent prostate cancer increased with SES means one of the following. First, the risk factors for prostate cancer are increased in the high SES group, which actually increases the incidence and prevalence of prostate cancer. However, as described earlier, the risk factors for prostate cancer are still unclear (Platz and Giovannucci, 2006), and there is currently no evidence that the risk factors affecting only the high SES group have surged in recent decades in Korea. Second, the low SES group underwent less prostate cancer screening, leading to a higher mortality rate, which lowered the prevalence of prostate cancer in the lower SES group, suggesting a higher prevalence of prostate cancer in the high SES group. However, this hypothesis cannot explain our finding that the mortality rate of prostate cancer remained almost unchanged in the years 2000–2016. Finally, it is possible that the high SES group underwent more PSA screening and more prostate cancer was found than in the low SES group. Although the Korean national cancer screening program requires the entire Korean population to receive screening for five cancers (stomach, breast, colorectal, cervical, and liver) (Suh et al., 2016), prostate cancer screening is not included in this essential cancer screening program and additional personal expenses are required to receive prostate cancer screening (Kim et al., 2011). Therefore, the higher the SES, the higher the frequency of PSA testing, the greater the detection rate of prostate cancer, the better access to health care, and eventually the higher survival rate. As a result, the prevalent prostate cancer increases with a higher SES. Our finding that prevalent prostate cancer increased with SES suggests overdiagnosis for several reasons. First, the incidence increased sharply, but the mortality did not change. This is a typical feature of overdiagnosis (Welch and Black, 2010) as seen in overdiagnosis of thyroid cancer in Korea. In addition, our results demonstrated that the incidence of prostate cancer has increased sharply from 2000 to 2011, and has suddenly decreased since 2012. Interestingly, from 2011, the media began to pay attention to overdiagnosis of thyroid cancer (Korea Times, 2014). Since then, the incidence of thyroid cancer in Korea has decreased significantly (annual percentage change in 1999-2011: 22.4, in 2011-2015: -14.4) (Jung et al., 2018), similar to the incidence of prostate cancer. These results suggest that the social impact of the overdiagnosis of thyroid cancer might similarly affect the incidence of prostate cancer. Second, the result is because of the nature of prostate cancer itself. Prostate cancer occurs frequently in men, but progresses very slowly and has a long survival period, so there is controversy over the effects and necessity of early screening (Etzioni et al., 2002). The autopsy results of people who died from causes other than prostate cancer found that 52% of patients over age 50 and 77% of patients over age 70 had prostate cancer (Hoffman, 2011). Third, as in the developed countries, the increase in prostate cancer in Korea is mainly due to an increase in PSA testing. Although PSA tests are mainly used as early screening for prostate cancer, there is little evidence that PSA tests can reduce prostate cancer mortality (Andriole et al., 2012). In a systematic review, the sensitivity and specificity of the PSA test were only 21% and 91%, respectively, based on a level of 4 ng/mL, suggesting that the PSA test is an incomplete screening tool (Wolf et al., 2010). In a follow-up study of PSA screening and control groups in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial with 76,693 men, the PSA screening group had a higher incidence of prostate cancer, but prostate cancer mortality was not significantly different between the two groups (Andriole et al., 2012). The European Randomized Study of Screening for Prostate Cancer (ERSPC) observed the PSA screening group and control group at nine centers in eight countries for 13 years; the mortality rate of the PSA screening group was significantly lower in only two centers (the Swedish and Dutch centers), and there were no significant differences in the other seven centers (Schröder et al., 2014). This study has several limitations. First, it was impossible to clearly present cause-and-effect relationships because a cross-sectional survey was used. Second, prevalent prostate cancer was estimated by referring to questionnaire data rather than medical records. Third, there were no data on tumor size, cancer stage, or histopathology. In conclusion, prevalent prostate cancer increased significantly with household income and education level and the increase in prevalent prostate cancer in Korea may not be due to an actual increase in prevalence, but to early detection such as PSA screening.
  27 in total

Review 1.  Overdiagnosis in cancer.

Authors:  H Gilbert Welch; William C Black
Journal:  J Natl Cancer Inst       Date:  2010-04-22       Impact factor: 13.506

2.  Overview of the National Cancer screening programme and the cancer screening status in Korea.

Authors:  Yeonju Kim; Jae Kwan Jun; Kui Sun Choi; Hoo-Yeon Lee; Eun-Cheol Park
Journal:  Asian Pac J Cancer Prev       Date:  2011

3.  Korea's thyroid-cancer "epidemic"--screening and overdiagnosis.

Authors:  Hyeong Sik Ahn; Hyun Jung Kim; H Gilbert Welch
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

4.  Risk factors for prostate cancer: A multifactorial case-control study.

Authors:  Saima Shakil Malik; Rakshanda Batool; Nosheen Masood; Azra Yasmin
Journal:  Curr Probl Cancer       Date:  2018-02-09       Impact factor: 3.187

5.  Associations between community income and cancer incidence in Canada and the United States.

Authors:  W J Mackillop; J Zhang-Salomons; C J Boyd; P A Groome
Journal:  Cancer       Date:  2000-08-15       Impact factor: 6.860

6.  Prostate Cancer and Socioeconomic Status in the Finnish Randomized Study of Screening for Prostate Cancer.

Authors:  Tuomas P Kilpeläinen; Kirsi Talala; Jani Raitanen; Kimmo Taari; Paula Kujala; Teuvo L J Tammela; Anssi Auvinen
Journal:  Am J Epidemiol       Date:  2016-11-15       Impact factor: 4.897

7.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Claudine Isaacs; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Ann W Hsing; Grant Izmirlian; Paul F Pinsky; Barnett S Kramer; Anthony B Miller; John K Gohagan; Philip C Prorok
Journal:  J Natl Cancer Inst       Date:  2012-01-06       Impact factor: 13.506

8.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen
Journal:  Lancet       Date:  2014-08-06       Impact factor: 79.321

9.  The association between the socioeconomic status and thyroid cancer prevalence; based on the Korean National Health and Nutrition Examination Survey 2010-2011.

Authors:  Seong-Woo Choi; So-Yeon Ryu; Mi-ah Han; Jong Park
Journal:  J Korean Med Sci       Date:  2013-11-26       Impact factor: 2.153

10.  Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015.

Authors:  Kyu-Won Jung; Young-Joo Won; Hyun-Joo Kong; Eun Sook Lee
Journal:  Cancer Res Treat       Date:  2018-03-21       Impact factor: 4.679

View more
  3 in total

1.  Influence of repeated prostate-specific antigen screening on treatment pattern in a country with a limited social perception of prostate cancer: Korean national wide observational study.

Authors:  Young Hwii Ko; Sang Won Kim
Journal:  Investig Clin Urol       Date:  2021-03-29

2.  The national-wide incidence of prostate-specific antigen testing trend for a decade in Korea by age group.

Authors:  Young Hwii Ko; Kwon-Chan Roh; Byung Hoon Kim
Journal:  Investig Clin Urol       Date:  2022-03

3.  RNA interference mediated suppression of TRPV6 inhibits the progression of prostate cancer in vitro by modulating cathepsin B and MMP9 expression.

Authors:  Duk Yoon Kim; Soon Hee Kim; Eun Kyoung Yang
Journal:  Investig Clin Urol       Date:  2021-05-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.